LAG3 and mesothelioma: In a mesothelioma mouse model, Marcq et al. [60] found that monotherapy with an immune checkpoint blocking antibody against PD-1 and its combination with another blocking antibody against LAG-3 resulted in delayed tumor growth and survival benefits in experimental mice.